Hepatitis A Vaccine

Product Details:

• It is a sterile suspension containing formaldehyde-inactivated hepatitis A virus (HM175 hepatitis A virus strain) adsorbed onto aluminum hydroxide.

• It is indicated for active immunization against disease caused by hepatitis A virus (HAV).
• It is approved for use in persons 12 months of age and older.
• Primary immunization should be administered at least 2 weeks prior to anticipated exposure to HAV.

• It should not be administered to subjects with known hypersensitivity to any component of the vaccine preparation or component of the container, or to subjects having shown signs of hypersensitivity after previous Havrix administration.
• As with other vaccines, the administration of Havrix should be postponed in subjects with severe febrile illness. The presence of a minor infection however, is not a contraindication.

• As with other injectable vaccines, appropriate medication (e.g. adrenaline) should be readily available for immediate use in case of anaphylaxis or anaphylactoid reactions following administration of the vaccine.
• For this reason, the vaccinee should remain under medical supervision for 30 minutes after immunization.
• Syncope (fainting) can occur following, or even before, any vaccination as a psychogenic response to the needle injection.
• It is important that procedures are in place to avoid injury from faints.

• It should be administered with caution to subjects with thrombocytopenia or a bleeding disorder since bleeding may occur following an intramuscular administration to these subjects.

• It is possible that subjects may be in the incubation period of hepatitis A infection at the time of immunization.
• It is not known whether it will prevent hepatitis A in such cases.
• Since there is a possibility that the vaccine may contain trace amounts of neomycin, the possibility of an allergic reaction in individuals sensitive to this substance should be kept in mind when considering the use of this vaccine.
• As with other vaccines, subjects with an impaired immune system may not obtain adequate antibody titres after the primary immunization course.
• Such patients may require administration of additional dose.
• However, no specific dosing recommendations can be made at this time.

• As with other vaccines, hemodialysis patients may not obtain adequate antibody titres after the primary immunization course.
• Such patients may require administration of additional dose.
• However, no specific dosing recommendations can be made at this time.

Product Details:

• HAV inactivated

• Prevention of infection caused by hepatitis A virus in adolescents 16 years and in adults.
• Vaccination against viral hepatitis A for subjects at risk of exposure to hepatitis virus including Non-immunized adolescents 16 years and adults travelling in endemic areas; adults at risk of contamination through their work Nursery personnel, personnel in residential institutions and homes for handicapped children and young people, sewage and water treatment personnel, food industry and catering personnel; adolescents 16 years living in residential institutions and homes for handicapped children and young people; adolescents 16 years and adults exposed to specific risks Haemophilia, multiple transfusions, IV drug addiction and homosexual practices; adolescents 16 years and adults chronically infected with hepatitis B virus.
• Avaxim 160 U does not protect against infection due to other types of hepatitis virus or to other known pathogens of the liver.

• The primary vaccination consists of 1 single dose of vaccine followed by a booster injection 6-12 months later.

• It is recommended that Avaxim 160 U be administered by the IM route in order to minimize local reactions.
• The recommended injection site is the deltoid region (upper arm muscle).
• In exceptional cases, Avaxim 160 U may be administered SC in patients suffering from thrombocytopenia (inadequate amount of platelets, a specific blood component with an important role in blood clotting) or in patients at risk of hemorrhages.

• Avaxim 160 U should not be used in the event of fever, acute illness and chronic progressive disease (it is preferable to postpone vaccination).
• Hypersensitivity to one of the components of Avaxim 160 U or following a previous injection.

• Do not inject by the intravascular route; ensure that the needle does not enter a blood vessel.
• Avaxim 160 U is not to be injected into the buttocks (due to the presence of varying amounts of adipose tissue) nor administered intradermally, since these routes of administration may induce a weaker immune response.
• Immunosuppressant treatment or a state of immune deficiency may lead to a diminished immune response to the vaccine.
• Vaccination may have no effect on the development of hepatitis A if administered during the incubation period of the disease.

• Use with caution in subjects with liver disease and those who are hypersensitive to neomycin (each dose of the vaccine contains trace amounts of neomycin).
• Avaxim 160 U contains formaldehyde as an excipient, which may have an effect in some patients.

Product Details:

• Biovac A Vaccine is freeze dried live atttenuated vaccine used for prevention of Hepatitis A infection.

• Your doctor or nurse will give you this medicine.
• Kindly do not self administer.

• Biovac A Vaccine is an inactivated vaccine (made from a dead virus).
• It helps develop immunity by forming antibodies, which are proteins that protect against infection caused by viruses present in the vaccine.

• Nausea, Pain, Pharyngitis, Abdominal pain, Anaphylactic reaction, Convulsion, Fatigue, Fever, Headache, Loss of appetite, Feeling of discomfort, Skin redness, Tenderness, Vomiting, Warm sensation.

• It is a vaccine used to prevent hepatitis A infection.
• Hepatitis A is a liver disease which spreads through food or water containing hepatitis A virus or by direct contact with an infected person.
• It should be stored in the refrigerator at 2 Degree to 8 DegreeC.
• Do not freeze.
• Let your doctor know if you have a high fever, serious illness or a weakened immune system.

• Alcohol: Interaction with alcohol is unknown. Please consult your doctor.
• Pregnancy: Biovac A Vaccine may be unsafe to use during pregnancy. Animal studies have shown adverse effects on the foetus, however, there are limited human studies. The benefits from use in pregnant women may be acceptable despite the risk. Please consult your doctor.
• Lactation: Biovac A Vaccine is safe to use during lactation. Human studies have shown that either the drug does not pass into the breastmilk in significant amount or is not expected to cause toxicity to the baby.
• Driving: It is not known whether Biovac A Vaccine alters the ability to drive. Do not drive if you experience any symptoms that affect your ability to concentrate and react.
• Kidney: Biovac A Vaccine is probably safe to use in patients with kidney disease. Limited data available suggests that dose adjustment of Biovac A Vaccine may not be needed in these patients. Please consult your doctor.
• Liver: Biovac A Vaccine is probably safe to use in patients with liver disease. Limited data available suggests that dose adjustment of Biovac A Vaccine may not be needed in these patients. Please consult your doctor.